AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05573724
- Locations
- 🇷🇴
Research Site, Cluj-Napoca, Romania
PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
Recruiting
- Conditions
- Breast NeoplasmsBreast CancerNeoplasm Metastasis
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 800
- Registration Number
- NCT05573893
- Locations
- 🇩🇪
Research Site, Zittau, Germany
A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI HFO Compared With BGF MDI HFA
Phase 1
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 108
- Registration Number
- NCT05569421
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
eVusheld Assessment reaL wORld Effectiveness in DoD Health System
Not yet recruiting
- Conditions
- COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
- Interventions
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6000
- Registration Number
- NCT05569408
- Locations
- 🇺🇸
Research Site, Bethesda, Maryland, United States
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
Phase 1
Completed
- Conditions
- NAFLDNonalcoholic Fatty Liver DiseaseNonalcoholic SteatohepatitisNASHNon-alcoholic Fatty Liver DiseaseFatty Liver, Nonalcoholic
- Interventions
- Drug: AZD7503 Intervention
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 19
- Registration Number
- NCT05560607
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 210
- Registration Number
- NCT05557838
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
- First Posted Date
- 2022-09-28
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT05557695
- Locations
- 🇬🇧
Research Site, Wigan, United Kingdom
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
Phase 3
Completed
- Conditions
- Asthma
- Interventions
- Combination Product: PT027Combination Product: PT007
- First Posted Date
- 2022-09-26
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 21
- Registration Number
- NCT05555290
- Locations
- 🇺🇸
Research Site, Columbia, Maryland, United States
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 14
- Registration Number
- NCT05551897
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Combination Product: Benralizumab
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 45
- Registration Number
- NCT05552508
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath